MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) unveiled new clinical data suggesting its investigational therapy buntanetap may ...

A study published Monday in JAMA Neurology reports that people with untreated obstructive sleep apnea (OSA) face a higher ...

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology ...

A recent study published in the journal Npj Parkinson's Disease investigated whether increased thinning rate in the parafoveal ganglion cell-inner plexiform layer (pfGCIPL) and peripapillary retinal ...

Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology.

Some people with Parkinson’s disease have cognitive abilities that remain stable over time, while others’ worsens, a new study finds. Early problems with visual processing and spatial reasoning are ...

Millions worldwide grapple with neurodegenerative diseases like Alzheimer's and Parkinson's. While both worsen over time, ...

A significant number of Parkinson's disease patients experience changes in their sense of smell, such as impaired olfactory function. Changes in the ...

A leading neurologist is working with the Amsterdam museum to see if making or encountering art can help ease symptoms of the ...

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...

Survey data showed that a third of Parkinson's patients reported a cognitive symptom soon after diagnosis. Most common were problems with memory, language or word finding, and concentration or ...